Polarean Imaging Share Discussion Threads

[actybod] 16/6/2021 13:21

I'm expecting £100 not 100p in years to come. Breakthrough tech and Covid shone a spot light on pulmonary. Now then...

[markstevenkirby80] 16/6/2021 10:44

You just need a bit of patience this is the one I will hold for a few years, it's definitely a no-brainer, come now 200p ++

[actybod] 16/6/2021 10:40

Not sure what was holding it back so much. The questor article given it a boost.

[markstevenkirby80] 16/6/2021 10:33

Yes nice , we can finally leave first gear,

[actybod] 16/6/2021 10:10

100 come now

[markstevenkirby80] 16/6/2021 09:23

100p incoming

[rhatton] 16/6/2021 08:34

Nice to get some mainstream mention

Offer is getting close to the £ mark once again :)

[40 fathoms] 16/6/2021 07:31

Today's Telegraph

Questor: Long Covid Breathes Yet More Life Into This Maker of MRI Image Enhancers
 
By Richard Evans
(Telegraph) -- After last week’s column on a new type of electric cable, today we cover a company that seems poised to reinvent medical scanning. All such tips must come with a health warning: with any technological breakthrough there is the chance that the potential is never realised, for a myriad reasons, and that shares in the companies behind them ultimately disappoint.
With that caveat in mind we’ll take a look at Aim-quoted Polarean and its clever way to make images of lungs, and in time perhaps of other organs, of enormously improved quality and resolution.
Its method is to get patients about to have an MRI scan to inhale a special gas, “hyperpolarised” xenon. Xenon is an inert gas from the same family as helium so it doesn’t harm patients. Hyperpolarisation means aligning the nuclei of the xenon atoms to a high degree and it is done by a pair of processes called “optical pumping” and “spin exchange”.
In Polarean’s words, “hyperpolarisation means aligning (polarising) the nuclei of gases to a much greater extent than what is achieved by being in the MRI scanner. Even the largest magnets only align a tiny fraction of the nuclei (0.001pc). But hyperpolarisation can align them to nearly 100pc”. It said hyperpolarisation enhanced MRI signal strength “by five orders of magnitude”.
Readers who want to see the difference this makes to an MRI scan of the lungs need only look at the picture below. Defects that are hard or impossible to spot on the conventional scan (left) are clear in the enhanced one (right).
“Setting aside the possibility that other organs can be scanned this way, the lungs alone have vast potential,” said Chris Boxall of Fundamental Asset Management, which has a stake in Polarean.
Another shareholder is Harry Spencer Walsh of Tyndall Investment Management. He said: “COPD [chronic obstructive pulmonary disease] is the third biggest cause of death globally. Sixteen million Americans suffer from it and 50pc of all adults in the US have low lung function.” He said accurate lung scans could lead to much better diagnosis and treatment.
“If you go to the doctor with breathing problems he or she gets you to blow into a tube to test lung function and will probably prescribe an inhaler. If it doesn’t help you’ll probably be given a different inhaler to try. The doctor doesn’t really know what’s wrong, even which lung has the problem. A high-resolution scan allows you to pinpoint the problem.”
Now we have long Covid too. Spencer Walsh said Prof Fergus Gleeson of Oxford University had been using Polarean’s technique to investigate the effects of long Covid on the lungs. “Normal scans showed them functioning normally. They didn’t show where in the lungs the problem was,” he added. Prof Gleeson said his follow-up scans using hyperpolarised xenon MRI “have found that abnormalities not normally visible on regular scans are indeed present”.
We must acknowledge that despite all this potential Polarean has not yet sold a single polariser to a hospital for regular use; its only sales so far have been for research purposes. This should all change if America’s Food & Drug Administration approves the company’s application for regulatory approval. A decision is due in October and it’s encouraging that the FDA was consulted beforehand about the matters that needed to be addressed in the application.
Should authorisation be granted, the financial as well as medical benefits should quickly be visible. Boxall said Polarean was already talking to hospitals with a view to making sales quickly. “It shouldn’t be difficult to sell,” he said. It helps that Polarean’s kit is relatively inexpensive next to the cost of the MRI scanner itself.
Spencer-Walsh added: “It’s obviously loss-making at the moment. Its broker forecasts profitability by 2025, then $167m (£119m) of sales in 2030 and profits of $60m. It expects 40pc annual growth in the early years, then 30pc by 2028-29. But it will be bought by then, possibly by Bracco Imaging of Italy, one of its biggest shareholders.
“My biggest fear is that it will be bought too soon. Depending on timing, it could fetch £500m-£1bn, against £194m now.”
Questor says: speculative buy
Ticker: POLX
Share price at close: 93p

[rhatton] 10/6/2021 13:16

Buys going through at 92.1

[richardjohn10] 04/6/2021 09:32

I would of said large buys getting worked?

[actybod] 04/6/2021 09:15

Big sells holding it back? Been like that for weeks. Will check for delayed sells later.

[markstevenkirby80] 04/6/2021 08:57

Very surprised it's not over 100p , superior to anything else on the market

[blueflame] 04/6/2021 08:46

Pivotal few months coming up for Polarean. Exciting times for shareholders.

[moontheloon] 04/6/2021 07:19

Polarean Imaging PLC Final ResultsSource: UK Regulatory (RNS & others)TIDMPOLXRNS Number : 7908APolarean Imaging PLC04 June 2021Polarean Imaging Plc("Polarean" or the "Company")Final Results for the Year Ended 31 December 2020Notice of Annual General MeetingPolarean Imaging plc (AIM: POLX), the medical - imaging technology company, with an investigational drug - device combination product for magnetic resonance imaging (MRI), announces its audited final results for the year ended 31 December 2020 .In addition, Polarean confirms that the Annual Report and Accounts for the year ended 31 December 2020, the Notice of the Annual General Meeting ("AGM") and a Form of Proxy are now available on the Company's website ( ) and will be posted to shareholders shortly.Polarean's AGM will be held at 2500 Meridian Parkway, Suite 175, Durham, NC 27713, USA at 2pm BST / 9am EST on 13 July 2021.Highlights-- Positive top-line results from the Phase III clinical trials using hyperpolarised (129) Xenon gas, where both trials met their primary endpoint-- Raised GBP8.4 million (gross), including a GBP2.2 million subscription from new strategic investor Bracco Imaging S.p.A. ("Bracco")-- Appointment of Jonathan Allis as Non-Executive Chairman -- Appointment of Cyrille Petit as Non-Executive Director and representative of Bracco -- Completion of a pre-New Drug Application ("NDA") meeting with the United States Food and Drug Administration ("FDA") -- Acceptance of the NDA for review by the FDA, with a target Prescription Drug User Fee Act ("PDUFA") action date of 5 October 2021-- Net cash of US$6.3 million as of 31 December 2020 Post-period end-- Raised GBP27 million gross proceeds in an oversubscribed financing, including continued support of strategic investors, Bracco Imaging S.p.A and Nukem Isotopes GmbH as well as institutional investor Amati AIM VCT plc, joined by several new UK and US institutional investors.-- Appointment of Chuck Osborne, Chief Financial Officer, to the Board -- Completion of Mid-Cycle Review of NDA submission with FDA -- Publication of first peer reviewed COVID research by Professor Fergus Gleeson at the University of Oxford-- Additional research unit order for a 9820 Xenon Polariser system from the University of British Columbia in Vancouver, Canada.Richard Hullihen, CEO of Polarean, commented: "It has been a strong year for Polarean, and we have achieved some significant milestones during the period beginning with the positive readout of our Phase III clinical trials in early 2020. This was followed quickly by a successful placing and subscription in April 2020, and a further oversubscribed fundraise in March 2021 which was needed to fund sales and marketing expenses to build the commercial team and infrastructure, to support ongoing clinical trial, regulatory and medical affairs costs, to support the continued investment in research and development and to provide additional working capital and for general corporate purposes."We have made significant Board changes to reflect our progress and we're very excited to have a target PDUFA date from the FDA. On behalf of the whole Board, I would like to thank our employees and shareholders for their ongoing support, and we look forward to further positive updates throughout the rest of the year."This announcement contains inside information for the purposes of Article 7 of Regulation (EU) 596/2014.Enquiries:

[rhatton] 02/6/2021 11:06

After some consolidation looks like we could be on the move again

[markstevenkirby80] 01/6/2021 09:39

Small top up ,

[actybod] 29/5/2021 15:50

Wonder if the price has been kept down for this. Lots of buying pressure - thought we would be over 100p with all the recent news. It will come

[4053777] 28/5/2021 22:49

Had a wee bit spare cash / billion pound company confident:)

[rhatton] 28/5/2021 19:42

Large trade to go into the weekend with

[markstevenkirby80] 28/5/2021 08:16

Happy weekend everyone,lookin forward for a pint or 2,

[markstevenkirby80] 27/5/2021 10:16

Yes the prize is just waiting for you ,

[4053777] 27/5/2021 08:44

This will blow above ASOS record share price / on Aim ? Hold for gold :)

[actybod] 26/5/2021 17:49

100k sale but 140k buys. It was nt this morning. Might see another big one tmrw.